Andrew Cooper
Stock Analyst at Raymond James
(2.36)
# 2,426
Out of 5,182 analysts
130
Total ratings
42.19%
Success rate
-0.18%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $25.04 | +79.71% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $90.20 | +5.32% | 4 | Oct 24, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $8.52 | +87.79% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $61.62 | +26.58% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $90.36 | -32.49% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $93.96 | +22.39% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $526.60 | +1.60% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $5.08 | +96.85% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $16.25 | +53.85% | 2 | May 5, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $202.38 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $194.75 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.42 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $208.40 | -59.21% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $12.71 | +497.95% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.61 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.35 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.80 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.16 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $25.04
Upside: +79.71%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $90.20
Upside: +5.32%
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $8.52
Upside: +87.79%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $61.62
Upside: +26.58%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $90.36
Upside: -32.49%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $93.96
Upside: +22.39%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $526.60
Upside: +1.60%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $5.08
Upside: +96.85%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $16.25
Upside: +53.85%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $202.38
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $194.75
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $21.42
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $208.40
Upside: -59.21%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $12.71
Upside: +497.95%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.61
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.35
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.80
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.16
Upside: -